203 related articles for article (PubMed ID: 24141294)
1. Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil.
Silva-Pinto AC; Angulo IL; Brunetta DM; Neves FI; Bassi SC; Santis GC; Covas DT
Sao Paulo Med J; 2013; 131(4):238-43. PubMed ID: 24141294
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
3. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
Borba R; Lima CS; Grotto HZ
J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.
Keikhaei B; Yousefi H; Bahadoram M
Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
6. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
7. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM
Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582
[TBL] [Abstract][Full Text] [Related]
8. Sickle cell anemia with systemic lupus erythematosus: response to hydroxyurea therapy.
Shetty AK; Kumar SR; Gedalia A; Warrier RP
J Pediatr Hematol Oncol; 1998; 20(4):335-7. PubMed ID: 9703008
[TBL] [Abstract][Full Text] [Related]
9. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
[TBL] [Abstract][Full Text] [Related]
10. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
[TBL] [Abstract][Full Text] [Related]
12. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
13. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
[TBL] [Abstract][Full Text] [Related]
14. [Effect of hydroxyurea on hemoglobin S].
Torres AF; Eberle SE; Sciuccati G; Bonduel M
Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083
[TBL] [Abstract][Full Text] [Related]
15. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.
Estepp JH; Smeltzer MP; Kang G; Li C; Wang WC; Abrams C; Aygun B; Ware RE; Nottage K; Hankins JS
Am J Hematol; 2017 Dec; 92(12):1333-1339. PubMed ID: 28913922
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
17. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
[TBL] [Abstract][Full Text] [Related]
18. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers.
Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE
Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480
[TBL] [Abstract][Full Text] [Related]
19. Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease.
Barbu EA; Dominical VM; Mendelsohn L; Thein SL
PLoS One; 2019; 14(12):e0226583. PubMed ID: 31869367
[TBL] [Abstract][Full Text] [Related]
20. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]